Avatar Posted by worldpharmanews 85 days ago (http://www.worldpharmanews.com)
Category: Corporate | Tags: bayer
Bayer Schering Pharma and the University of Nagasaki (Japan) have signed a licensing agreement on the use of novel substances for molecular imaging. Being used as tracers in Positron Emission Tomography (PET), these compounds could make it possible to allow an early diagnosis of Alzheimer's disease. According to the agreement, Bayer Schering Pharma will receive exclusive worldwide rights to develop and market a set of radiolabeled molecules.
Discuss   Add this link to...  Bury

Comments Who Voted Related Links


News/Blogroll [ alliConnect | BioJobBlog | CNTO411 | Corey Nahman | eDrugSearch | Drug Injury Watch | EyeOnFDA | Forbes ScienceBiz | Healthy Skepticism | JNJ BTW | medGadget | Medical 2.0 | Pharma's Market at CNBC | PharmaFraud | PharmaGossip | Pharmalot | Polish Pharma Market | The Shark Report | World Pharma News | WSJ Health Blog ]
Pharmaceutical Companies [ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

About | Buttons | Contact | Terms and Conditions
Concept and Design by World Pharma News (.com) Project | Powered by Pligg based on PHP/MySQL.
Submit to World Pharma News .net